Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
← catalyst calendarNCT05198245 · readout in 607 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With RTI Health Solutions, Optum, Inc..
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-15 | actual | When the study began enrolling |
| Primary completion | 2028-04-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-17 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Rimegepant
- Drug: Various
- Other: No intervention
Primary outcome
what the primary-completion date above is the date OFMajor congenital malformations, spontaneous abortions, fetal deaths/stillbirths, small for gestational age births
measured Annually beginning April 2022
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed